Actelion Pharmaceuticals Ltd : Actelion nominates Mr. John J. Greisch for election to the Board of Directors

  Actelion Pharmaceuticals Ltd : Actelion nominates Mr. John J. Greisch for
                      election to the Board of Directors

Actelion Pharmaceuticals Ltd / Actelion nominates Mr. John J. Greisch for
election to the Board of Directors . Processed and transmitted by Thomson
Reuters ONE. The issuer is solely responsible for the content of this

ALLSCHWIL/BASEL, SWITZERLAND - 14 March  2013- Actelion Ltd (SIX: ATLN)  today 
issued the formal invitation to the  upcoming Annual General Meeting (AGM)  of 
shareholders on behalf of the Board of Directors.

At the  AGM the  Board is  nominating  Mr. John  J. Greisch  to the  Board  of 
Directors. Mr.  Greisch  is  currently  serving as  the  President  and  Chief 
Executive Officer of Hill-Rom Holdings, Inc.

Jean-Pierre Garnier,  Chairman of  the Board  of Directors,  commented: "As  a 
current CEO, John understands the challenges that face companies operating  in 
the current  economic and  business  climate. I  believe John's  strong  track 
record of success in  the healthcare industry  will add significant  practical 
business acumen to Actelion's Board."

In addition, delivering  on Actelion's  commitment to value  creation for  all 
stakeholders, the Board is proposing a  25% increase in the dividend  payment, 
increasing the payment to CHF 1.00 per share


1.Approval of the Business Report consisting of the Annual Report, the
    Annual Statutory Accounts and the Consolidated Accounts as of 31 December
2.Appropriation of Available Earnings and Distribution Against Reserve from
    Capital Contribution
3.Consultative Vote on Compensation Report
4.Discharge of the Board of Directors and of the Senior Management
5.Reduction of Share Capital by Cancellation of Repurchased Shares
6.Board Elections
    6.1Re-Election of Mr. Werner Henrich
    6.2 Re-Election of Mr. Armin Kessler
    6.3 Re-Election of Mr. Jean Malo
    6.4 Election of Mr. John J. Greisch as New Board Member
7.Election of the Statutory Auditors


The Annual General Meeting of Shareholders  to approve the Business Report  of 
the year ending 31 December 2012 will be  held on 18 April 2013 at 14.00  CEST 
at the Congress Center, Messe Basel, Switzerland.

The invitation has been  published in the Swiss  Official Gazette of  Commerce 
(Schweizerisches  Handelsamtsblatt)  and  is  available,  together  with   the 
company's Annual Report, on

In order to  attend and vote  at the Annual  General Meeting of  Shareholders, 
shareholders must have been registered  in the Company's shareholder  register 
by 9 April 2013 at the latest.




Mr. John J. Greisch is currently  President (as Executive Director) and  Chief 
Executive Officer of Hill-Rom  Holdings, Inc., a  leading medical supplier  of 
patient support  systems  such  as hospital  beds,  therapeutic  surfaces  and 
stretchers. Under Mr. Greisch's leadership, Hill-Rom increased its investments
in research  and development,  introducing new  smart bed  technology and  new 
surfaces to the market as  well as expanding its Singapore-based  Asia-Pacific 
Innovation Center.

Before  joining   Hill-Rom,  Mr.   Greisch  spent   seven  years   at   Baxter 
International, Inc.  in  various  executive positions  in  corporate  finance, 
operations  and  general  management.  From  2004-2006,  he  served  as  Chief 
Financial Officer and from 2006-2009 as President International Operations.

Mr Greisch  earned a  Bachelor's degree  in Business  Administration from  the 
Miami University, US and a Master's Degree in Management (MBA equivalent) from
the Northwestern University in Illinois, US

Mr. Greisch also serves on the  Board of Lurie Children's Hospital in  Chicago 
and is  a  past  member  of  the Business  School  Advisory  Board  for  Miami 
University's Farmer School of Business.


Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland.  Actelion's  first drug  Tracleer®,  an  orally 
available dual endothelin receptor antagonist, has been approved as a  therapy 
for pulmonary arterial hypertension.  Actelion markets Tracleer® through  its 
own subsidiaries in key markets worldwide, including the United States  (based 
in South  San Francisco),  the European  Union, Japan,  Canada, Australia  and 

Founded in  late 1997  Actelion  is a  leading  player in  innovative  science 
related to the endothelium - the single layer of cells separating every  blood 
vessel from the blood  stream. Actelion's over 2,400  employees focus on  the 
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares  are traded on the  SIX Swiss Exchange  (ticker 
symbol: ATLN) as  part of the  Swiss blue-chip index  SMI (Swiss Market  Index 

For further information please contact:

Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36

Media Release PDF


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;
Press spacebar to pause and continue. Press esc to stop.